We expect that the mPEG × HER2-modified PLD can significantly increase the safety of targeted PLD-treated individual and susceptibility of HER2+ ovarian cancer cells to PLD, reduce the number of residual cancer cells and further decrease the frequency of relapse disease after PLD treatment. Here, ERBB2 is linked to ovarian cancer.